D-0140-2017 Class II Terminated
FDA drug recall D-0140-2017 was initiated by Sandoz Inc on Nov 9, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised. The recall status is terminated (terminated Oct 17, 2017). Affected quantity: 18,751 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2016
- Initiation Date
- Nov 9, 2016
- Termination Date
- Oct 17, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 18,751 vials
Product description
L-Cysteine Hydrochloride Injection, USP, 0.5 g/10 mL (50 mg/mL), 10 mL Single Dose Vial (NDC 66758-004-01), packaged in 10 x 10mL Vials per carton (NDC 66758-004-02), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540.
Reason for recall
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.
Distribution pattern
Nationwide throughout the USA
Code information
Lot #: 2081915, 2082015, 2082115, 2082815, 2083115, Exp 08/17; 2090115, Exp 09/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0140-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026